先前接受维奈克拉治疗后接受化疗加维奈克拉治疗的髓系肿瘤患者的结局
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.
作者信息
Madero-Marroquin Rafael, Cannova Joseph, Dworkin Emily, Wesevich Austin, Roloff Gregory W, Saygin Caner, Nawas Mariam T, DuVall Adam S, Kosuri Satyajit, Thirman Michael J, Odenike Olatoyosi, Stock Wendy, Larson Richard A, Drazer Michael W, Patel Anand A
机构信息
Section of Hematology/Oncology Department of Medicine University of Chicago Chicago Illinois USA.
Department of Pharmacy University of Chicago Medicine Chicago Illinois USA.
出版信息
EJHaem. 2025 Jun 13;6(3):e70078. doi: 10.1002/jha2.70078. eCollection 2025 Jun.
BACKGROUND
Outcomes for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that have progression after treatment with hypomethylating agent (HMA) and venetoclax (VEN) are poor. However, data for chemotherapy and VEN (C+VEN) therapy after prior treatment with HMA+VEN are limited.
METHODS
We identified 18 patients with AML or MDS/AML who received C+VEN after prior HMA+VEN.
RESULTS
Complete remission (CR) or CR with incomplete hematologic recovery (CRi) was achieved in 7 patients (39%) and 6 patients (33%) proceeded to allogeneic hematopoietic stem cell transplantation.
CONCLUSION
This study shows suggests that C+VEN could be a viable option in a subset of patients after HMA+VEN.
背景
急性髓系白血病（AML）或骨髓增生异常综合征（MDS）患者在接受去甲基化药物（HMA）和维奈克拉（VEN）治疗后病情进展，其预后较差。然而，在先前接受HMA+VEN治疗后进行化疗和VEN（C+VEN）治疗的数据有限。
方法
我们纳入了18例在先前接受HMA+VEN治疗后接受C+VEN治疗的AML或MDS/AML患者。
结果
7例患者（39%）实现完全缓解（CR）或伴有血液学不完全恢复的CR（CRi），6例患者（33%）进行了异基因造血干细胞移植。
结论
本研究表明，C+VEN可能是HMA+VEN治疗后一部分患者的可行选择。
Zotero 插件